These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31338095)

  • 1. Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure.
    Ray K; Mengistu M; Orlandi C; Pazgier M; Lewis GK; DeVico AL
    Front Immunol; 2019; 10():1512. PubMed ID: 31338095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic properties of the HIV envelope on virions in solution.
    Ray K; Mengistu M; Yu L; Lewis GK; Lakowicz JR; DeVico AL
    J Virol; 2014 Feb; 88(3):1795-808. PubMed ID: 24284318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrete partitioning of HIV-1 Env forms revealed by viral capture.
    Stieh DJ; King DF; Klein K; Aldon Y; McKay PF; Shattock RJ
    Retrovirology; 2015 Sep; 12():81. PubMed ID: 26399966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.
    Lee JH; Leaman DP; Kim AS; Torrents de la Peña A; Sliepen K; Yasmeen A; Derking R; Ramos A; de Taeye SW; Ozorowski G; Klein F; Burton DR; Nussenzweig MC; Poignard P; Moore JP; Klasse PJ; Sanders RW; Zwick MB; Wilson IA; Ward AB
    Nat Commun; 2015 Sep; 6():8167. PubMed ID: 26404402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
    Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
    J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.
    Mengistu M; Tang AH; Foulke JS; Blanpied TA; Gonzalez MW; Spouge JL; Gallo RC; Lewis GK; DeVico AL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):E9893-E9902. PubMed ID: 29087304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.
    Falkowska E; Le KM; Ramos A; Doores KJ; Lee JH; Blattner C; Ramirez A; Derking R; van Gils MJ; Liang CH; Mcbride R; von Bredow B; Shivatare SS; Wu CY; Chan-Hui PY; Liu Y; Feizi T; Zwick MB; Koff WC; Seaman MS; Swiderek K; Moore JP; Evans D; Paulson JC; Wong CH; Ward AB; Wilson IA; Sanders RW; Poignard P; Burton DR
    Immunity; 2014 May; 40(5):657-68. PubMed ID: 24768347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS; Gnanapragasam PN; Galimidi RP; Foglesong CP; West AP; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7385-90. PubMed ID: 19372381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
    Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
    PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells.
    Mengistu M; Ray K; Lewis GK; DeVico AL
    PLoS Pathog; 2015 Mar; 11(3):e1004772. PubMed ID: 25807494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.
    Blattner C; Lee JH; Sliepen K; Derking R; Falkowska E; de la Peña AT; Cupo A; Julien JP; van Gils M; Lee PS; Peng W; Paulson JC; Poignard P; Burton DR; Moore JP; Sanders RW; Wilson IA; Ward AB
    Immunity; 2014 May; 40(5):669-80. PubMed ID: 24768348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240.
    Gohain N; Tolbert WD; Orlandi C; Richard J; Ding S; Chen X; Bonsor DA; Sundberg EJ; Lu W; Ray K; Finzi A; Lewis GK; Pazgier M
    Sci Rep; 2016 Nov; 6():36685. PubMed ID: 27827447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.
    Wang P; Yang X
    J Virol; 2010 Jul; 84(14):7114-23. PubMed ID: 20463081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.